Serum markers of bone metastases in postmenopausal breast cancer patients treated with formestane

Antonia Martinetti, Emilio Bajetta, Ettore Seregni, Nicoletla Zilembo, Leonardo Ferrari, Cristina Noberasco, Simonetta Massaron, Lorenza Rimassa, Emilio Bombardieri

Research output: Contribution to journalArticle

Abstract

Bone metabolism marker evaluation is expected to play an auxiliary role in the diagnosis and follow-up of bone metastases in patients affected by different types of neoplasms. In this study we have evaluated osteoblastic and osteoclastic markers in 18 patients with bone metastases from breast cancer at diagnosis and for I year of follow-up during treatment with the aromatase inhibitor formestane. Osteoblastic markers include the carboxy- terminal propeptide of type I procollagen, the bone-specific alkaline phosphatase and the bone GLA protein. The carboxy-terminal cross-linked telopeptide of type I collagen (ICTP) was evaluated as a marker of osteoclastic activity. The patients were classified into three groups according to clinical response. A good correlation between marker level modifications and clinical evolution of skeletal metastases was observed for all the examined markers. Patients with progressive disease showed increasing levels of all markers, whereas patients in regression showed a reduction compared to the basal levels; patients with stable disease fell in between these two categories. We also found that basal ICTP values have prognostic significance: in the stable and progressive disease group they were higher than in the partial response group.

Original languageEnglish
Pages (from-to)197-205
Number of pages9
JournalTumor Biology
Volume18
Issue number4
Publication statusPublished - 1997

Fingerprint

Biomarkers
Breast Neoplasms
Neoplasm Metastasis
Bone and Bones
Collagen Type I
Aromatase Inhibitors
Alkaline Phosphatase
formestane
Neoplasms
Therapeutics

Keywords

  • Bone metastases
  • Breast cancer
  • Hormonal treatment
  • Serum markers

ASJC Scopus subject areas

  • Cancer Research

Cite this

Serum markers of bone metastases in postmenopausal breast cancer patients treated with formestane. / Martinetti, Antonia; Bajetta, Emilio; Seregni, Ettore; Zilembo, Nicoletla; Ferrari, Leonardo; Noberasco, Cristina; Massaron, Simonetta; Rimassa, Lorenza; Bombardieri, Emilio.

In: Tumor Biology, Vol. 18, No. 4, 1997, p. 197-205.

Research output: Contribution to journalArticle

Martinetti, A, Bajetta, E, Seregni, E, Zilembo, N, Ferrari, L, Noberasco, C, Massaron, S, Rimassa, L & Bombardieri, E 1997, 'Serum markers of bone metastases in postmenopausal breast cancer patients treated with formestane', Tumor Biology, vol. 18, no. 4, pp. 197-205.
Martinetti, Antonia ; Bajetta, Emilio ; Seregni, Ettore ; Zilembo, Nicoletla ; Ferrari, Leonardo ; Noberasco, Cristina ; Massaron, Simonetta ; Rimassa, Lorenza ; Bombardieri, Emilio. / Serum markers of bone metastases in postmenopausal breast cancer patients treated with formestane. In: Tumor Biology. 1997 ; Vol. 18, No. 4. pp. 197-205.
@article{b3cfc5ab4f2e4e999d193c4573b950c8,
title = "Serum markers of bone metastases in postmenopausal breast cancer patients treated with formestane",
abstract = "Bone metabolism marker evaluation is expected to play an auxiliary role in the diagnosis and follow-up of bone metastases in patients affected by different types of neoplasms. In this study we have evaluated osteoblastic and osteoclastic markers in 18 patients with bone metastases from breast cancer at diagnosis and for I year of follow-up during treatment with the aromatase inhibitor formestane. Osteoblastic markers include the carboxy- terminal propeptide of type I procollagen, the bone-specific alkaline phosphatase and the bone GLA protein. The carboxy-terminal cross-linked telopeptide of type I collagen (ICTP) was evaluated as a marker of osteoclastic activity. The patients were classified into three groups according to clinical response. A good correlation between marker level modifications and clinical evolution of skeletal metastases was observed for all the examined markers. Patients with progressive disease showed increasing levels of all markers, whereas patients in regression showed a reduction compared to the basal levels; patients with stable disease fell in between these two categories. We also found that basal ICTP values have prognostic significance: in the stable and progressive disease group they were higher than in the partial response group.",
keywords = "Bone metastases, Breast cancer, Hormonal treatment, Serum markers",
author = "Antonia Martinetti and Emilio Bajetta and Ettore Seregni and Nicoletla Zilembo and Leonardo Ferrari and Cristina Noberasco and Simonetta Massaron and Lorenza Rimassa and Emilio Bombardieri",
year = "1997",
language = "English",
volume = "18",
pages = "197--205",
journal = "Tumor Biology",
issn = "1010-4283",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - Serum markers of bone metastases in postmenopausal breast cancer patients treated with formestane

AU - Martinetti, Antonia

AU - Bajetta, Emilio

AU - Seregni, Ettore

AU - Zilembo, Nicoletla

AU - Ferrari, Leonardo

AU - Noberasco, Cristina

AU - Massaron, Simonetta

AU - Rimassa, Lorenza

AU - Bombardieri, Emilio

PY - 1997

Y1 - 1997

N2 - Bone metabolism marker evaluation is expected to play an auxiliary role in the diagnosis and follow-up of bone metastases in patients affected by different types of neoplasms. In this study we have evaluated osteoblastic and osteoclastic markers in 18 patients with bone metastases from breast cancer at diagnosis and for I year of follow-up during treatment with the aromatase inhibitor formestane. Osteoblastic markers include the carboxy- terminal propeptide of type I procollagen, the bone-specific alkaline phosphatase and the bone GLA protein. The carboxy-terminal cross-linked telopeptide of type I collagen (ICTP) was evaluated as a marker of osteoclastic activity. The patients were classified into three groups according to clinical response. A good correlation between marker level modifications and clinical evolution of skeletal metastases was observed for all the examined markers. Patients with progressive disease showed increasing levels of all markers, whereas patients in regression showed a reduction compared to the basal levels; patients with stable disease fell in between these two categories. We also found that basal ICTP values have prognostic significance: in the stable and progressive disease group they were higher than in the partial response group.

AB - Bone metabolism marker evaluation is expected to play an auxiliary role in the diagnosis and follow-up of bone metastases in patients affected by different types of neoplasms. In this study we have evaluated osteoblastic and osteoclastic markers in 18 patients with bone metastases from breast cancer at diagnosis and for I year of follow-up during treatment with the aromatase inhibitor formestane. Osteoblastic markers include the carboxy- terminal propeptide of type I procollagen, the bone-specific alkaline phosphatase and the bone GLA protein. The carboxy-terminal cross-linked telopeptide of type I collagen (ICTP) was evaluated as a marker of osteoclastic activity. The patients were classified into three groups according to clinical response. A good correlation between marker level modifications and clinical evolution of skeletal metastases was observed for all the examined markers. Patients with progressive disease showed increasing levels of all markers, whereas patients in regression showed a reduction compared to the basal levels; patients with stable disease fell in between these two categories. We also found that basal ICTP values have prognostic significance: in the stable and progressive disease group they were higher than in the partial response group.

KW - Bone metastases

KW - Breast cancer

KW - Hormonal treatment

KW - Serum markers

UR - http://www.scopus.com/inward/record.url?scp=0030855621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030855621&partnerID=8YFLogxK

M3 - Article

C2 - 9218004

AN - SCOPUS:0030855621

VL - 18

SP - 197

EP - 205

JO - Tumor Biology

JF - Tumor Biology

SN - 1010-4283

IS - 4

ER -